Report The Panel agreed on the outline of the 2027 IPCC Methodology Report on Carbon Dioxide Removal Technologies, Carbon Capture, Utilization, and Storage for National Greenhouse Gas Inventories (Additional guidance) at its 63rd Session held in Lima, Peru from 27-30 October 2025 (Decision IPCC-LXIII-6). The report will be a single Methodology Report comprising an Overview Chapter and six volumes consistent with the format of the 2006 IPCC Guidelines for National Greenhouse Gas Inventories. The structure of the Methodology Report is consistent with the 2006 IPCC Guidelines so as to make it easier for inventory compilers to use this Methodology Report with the 2006 IPCC Guidelines. Topics that will be addressed include: Transport, injection and sequestering of CO2 in relation to enhanced oil, gas, and coal-bed methane recovery Production of products containing or derived from captured and/or removed CO2 Carbonation of cement and lime-based structures Soil carbon sinks and related emissions enhanced through biochar and weathering and other elements Coastal wetlands carbon dioxide removal types not in previous IPCC Guidelines as well as additional information on mangroves, tidal marshes and seagrass in coastal waters Durable biomass products Carbon dioxide capture from combustion and process gases Direct air capture Carbon dioxide utilisation Carbon dioxide transport including cross border issues Carbon dioxide injection and storage CO2 removal through direct capture of CO2 from water already processed by inland and coastal facilities; and related elements across the range of categories of the IPCC Guidelines. The national greenhouse gas inventory includes sources and sinks occurring within the territory over which a country has jurisdiction. Over 150 experts are expected to participate in the writing process, which will be completed by 2027. The participants will be selected by the Task Force Bureau taking into account scientific and technical expertise, geographical and gender balance to the extent possible in line with Appendix A to the Principles Governing IPCC Work. The First Lead Authors’ meeting will be held in Rome, Italy, in April 2026. Preparatory Work The decision by the Panel to prepare this Methodology Report was informed by the work of experts at the scoping meeting held in Copenhagen, Denmark, from 14-16 October 2024. Prior to the scoping meeting, an expert meeting was held at Vienna, Austria 1-3 July 2024. These meetings considered Carbon Dioxide Removal (CDR) methods mentioned in the AR6 WGIII Report as a starting point for discussion and noted that several CDR activities have been already covered by the existing IPCC Guidelines. More Information The IPCC Secretary has written to national government focal points inviting nominations of authors by 12 December 2025.

Fast Facts Medicaid programs that cover prescription drugs are generally required to cover drugs that are (1) FDA approved and (2) made by a manufacturer that participates in the Medicaid Drug Rebate Program. 13 Medicaid programs didn’t cover Mifeprex and its generic equivalent, Mifepristone Tablets, 200 mg, when required. These drugs are used for medical abortion. We recommended the Centers for Medicare & Medicaid Services ensure Medicaid programs comply with federal requirements for covering Mifepristone Tablets, 200 mg. We also reiterated our 2019 recommendation on Mifeprex, which hasn’t been implemented. White pills spilling from a pill bottle. Skip to Highlights Highlights What GAO Found Medicaid programs that choose to cover outpatient prescription drugs are required to cover all Food and Drug Administration (FDA) approved drugs for their medically accepted indications when those drugs are made by a manufacturer that participates in the Medicaid Drug Rebate Program (MDRP), except as outlined in federal law. The FDA has approved two drugs—Mifeprex in 2000 and its generic equivalent in 2019, referred to as Mifepristone Tablets, 200 mg—for the medical termination of an intrauterine pregnancy, known as a medical abortion. Danco Laboratories and GenBioPro are the exclusive manufacturers of Mifeprex and Mifepristone Tablets, 200 mg, respectively, and both manufacturers participate in the MDRP. Medicaid programs in all 50 states, the District of Columbia, and Puerto Rico cover prescription drugs and participate in the MDRP. According to officials from the Centers for Medicare & Medicaid Services (CMS)—the federal agency within the Department of Health and Human Services (HHS) responsible for ensuring Medicaid programs’ compliance—none of the MDRP’s statutory exceptions apply to Mifeprex or Mifepristone Tablets, 200 mg. Thus, these 52 Medicaid programs must cover these drugs when prescribed for medical abortion in circumstances eligible for federal funding, such as when the pregnancy is the result of rape or incest. GAO identified gaps in Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg. Officials from 35 of the 49 programs who responded to GAO questions said their programs covered Mifeprex and Mifepristone Tablets, 200 mg for medical abortion, as of December 31, 2024. In contrast, officials from 13 programs told GAO their programs did not cover either drug for medical abortion. An official from the remaining program did not specify the medical indications for which its program covered the drugs. Medicaid Programs’ Coverage of Danco Laboratories’ Mifeprex and GenBioPro’s Mifepristone Tablets, 200 mg, as of December 31, 2024 Note: For more details, see fig. 1 in GAO-25-107911. State officials’ responses to GAO’s questions indicated that some states may not be complying with the MDRP requirements for covering Mifeprex and Mifepristone Tablets, 200 mg. However, CMS has not determined the extent to which states comply with the MDRP requirements for these drugs. CMS officials told GAO they were not aware of the following: Nine programs did not cover Mifeprex and Mifepristone Tablets, 200 mg for any medical indication, as of December 31, 2024; GAO reported four of these programs did not cover Mifeprex in 2019. Mifepristone Tablets, 200 mg was not available at the time of GAO’s 2019 report. Four additional Medicaid programs did not cover either drug when prescribed for medical abortion, as of December 31, 2024. CMS was not aware of these coverage gaps, in part, because it had not implemented GAO’s 2019 recommendation to take actions to ensure Medicaid programs comply with MDRP requirements to cover Mifeprex. CMS also has not taken actions related to the coverage of Mifepristone Tablets, 200 mg, as of August 2025. Without such actions, CMS lacks assurance that Medicaid programs comply with MDRP requirements and Medicaid beneficiaries may lack access to these drugs when appropriate. Why GAO Did This Study GAO was asked to describe Medicaid programs’ coverage of mifepristone. This report examines Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg, among other things. GAO reviewed laws and CMS guidance on the MDRP, and coverage of Mifeprex and Mifepristone Tablets, 200 mg. GAO also sent written questions to officials from the 52 Medicaid programs that participate in the MDRP regarding their coverage of these drugs, and reviewed officials’ responses from the 49 programs that provided GAO information. Recommendations GAO reiterates its 2019 recommendation that CMS take actions to ensure states’ compliance with MDRP requirements to cover Mifeprex. GAO also recommends that CMS determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro’s Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. In response to the recommendation, HHS noted it is reviewing applicable law and will determine the best course of action to address it moving forward. Recommendations for Executive Action Agency Affected Recommendation Status Centers for Medicare & Medicaid Services The Administrator of CMS should determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro's Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. (Recommendation 1) Open Actions to satisfy the intent of the recommendation have not been taken or are being planned. When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information. Full Report Full Report (11 pages)

05.12.2025 – The European Scientific Advisory Board on Climate Change, established under the European Climate Law, will continue to be supported in its second term (2026-2030) by Ottmar Edenhofer. The Director of the Potsdam Institute for Climate Impact Research (PIK) has now been appointed by the Management Board of the European Environment Agency in Copenhagen for another four-year term on the Advisory Board, beginning on 24 March 2026. Advising EU policymakers on the path to the declared goal of climate neutrality: PIK Director Ottmar Edenhofer. Photo: PIK/Karkow The Advisory Board gives independent advice and produces reports on EU policies, and their coherence with the Climate Law and the EU’s commitments under the Paris Agreement. It consists of 15 high-level scientific experts covering a wide range of relevant fields. Edenhofer is serving as the Advisory Board’s current Chair during its first term (2022-2026). Highlights during this period have included scientific recommendations for an ambitious EU climate target for 2040, an analysis of the action needed to achieve climate neutrality, and a study on scaling up atmospheric carbon removals. “I am very thankful for the great opportunity to continue supporting EU climate policy in this service role for the next four years,” says Edenhofer, who is also Professor for The Economics and Politics of Climate Change at the Technische Universität Berlin. “The European Union has taken some important steps in recent years towards its declared goal of climate neutrality by 2050. It remains important to make climate policy cost-effective, socially balanced and consistent with the requirements of an internationally competitive economy. As a member of the Advisory Board, I will do my best to provide scientific advice to policymakers on this task.” The composition of the Advisory Board for the next four-year term has now been decided through an open, fair and transparent selection process lasting several months. The decision on who will chair the body in future is not expected until beginning of the second term. The other members of the Advisory Board in the second term are: • Annela Anger-Kraavi – University of Cambridge • Constantinos Cartalis – National and Kapodistrian University of Athens • Suraje Dessai – University of Leeds’ School of Earth, Environment, and Sustainability • Laura Díaz Anadón – University of Cambridge • Vera Eory – Scotland’s Rural College • Lena Kitzing - Technical University of Denmark • Kati Kulovesi – University of Eastern Finland • Lars J. Nilsson – Lund University • Åsa Persson – KTH Royal Institute of Technology’s Climate Action Centre • Keywan Riahi – International Institute for Applied Systems Analysis • Jean-François Soussana – French National Research Institute for Agriculture, Food and the Environment • Giorgio Vacchiano – University of Milan • Detlef van Vuuren – PBL Netherlands Environmental Assessment Agency • Zinta Zommers – University of Toronto

Abstract Polygenic scores (PGS) quantify genetic contributions to complex traits, yet existing single- and multi-ancestry methods lack multi-dimensional evaluation within a unified framework. Here, we benchmarked 13 state-of-the-art PGS methods across 36 traits in UK Biobank European and African samples. The prediction performance, computational efficiency, the number of variants, and the impact of different linkage disequilibrium (LD) reference sizes were thoroughly assessed for each method. Results of single-ancestry methods demonstrate that LDpred2 has superior performance across a broad spectrum of complex traits in terms of accuracy and computational efficiency; however, other methods remain valuable for specific traits. For multi-ancestry methods, PRS-CSx and X-Wing have comparable performance, whereas LDpred2-multi outperforms both. Notably, we find that increasing the panel size of the LD reference significantly elevates PGS performance for sample sizes below 1,000, and it reaches a plateau when it exceeds 5,000 samples. Furthermore, implementing PGS calculation methods requires considerable technical effort and resource allocation. To support easy use of these PGS methods, we developed a user-friendly online computing platform, PGS-hub, that integrates all evaluated methods and is pre-configured with ancestry-stratified LD panels. This resource enables a scalable and harmonized PGS computation platform for the PGS community.

Abstract The bacterial accessory genome, comprised of plasmids, phages, and other mobile elements, underpins the adaptability of bacterial populations. Pangenome (core and accessory) analysis of pathogens can reveal epidemiological relatedness missed by using core-genome methods alone. Employing a k-mer-based Jaccard Index approach to compute pangenome relatedness, we explore the population structure and epidemiology of Salmonella enterica serotype Hadar (Hadar), an emerging zoonotic pathogen in the United States (U.S.) linked to both commercial and backyard poultry. A total of 3384 U.S. Hadar genomes collected between 1990 and 2023 are analyzed here. Hadar populations underwent substantial shifts between 2019 and 2020 in the U.S., driven by the expansion of a lineage carrying a previously uncommon prophage-like element. Phylogenetic and pangenomic relatedness, coupled with epidemiological data, suggest this lineage emerged from extant populations circulating in commercial poultry, with subsequent dissemination into backyard poultry environments. We demonstrate the utility of pangenomic approaches for mapping vertical and horizontal diversity and informing complex dynamics of zoonotic bacterial pathogens.

Abstract Cas9 can process poly(T) single-stranded DNA molecules upon activation in an RNA-guided manner. Here, we uncover key determinants underlying this function. First, we show that unflanked R-loops in the RNA 5′ side favor trans-cleavage activity, which occur when targeting short double-stranded DNA molecules. Second, we show that elongated guide RNA spacers beyond the canonical 20 bases, even by a few bases, severely impair this collateral activity. Third, although trans-cleavage is mediated by the RuvC domain, we show that a catalytically active HNH domain contributes to an efficient process. Analysis of structural models provides tentative mechanistic insights. Together, these findings illustrate that fine modulation of Cas9 function can be achieved.

Abstract Conceptual engineering system design faces challenges from traditional methods and emerging AI tools to fully address its inherently complex, dynamic, and creativity-driven demands. iDesignGPT is a framework that integrates large language models with established design methodologies to enable dynamic multi-agent collaboration for problem refinement, information gathering, design space exploration, and evaluation. By incorporating design metrics such as coverage, diversity, and novelty, iDesignGPT provides quantitative insights for early-stage conceptual design. Performance evaluations across six public design challenges show that iDesignGPT achieves competitive novelty and consistently higher originality and modularity than GPT-4o zero-shot, GPT-4o chain-of-thought and Deepseek-r1, based on metrics and expert assessments. Two controlled user studies show positive reception across profiles and, for novice designers, lower mental demand than human-only design and clearer design flow with iDesignGPT. These results establish iDesignGPT as a practical framework for integrating language-model agents with established engineering design methods, enabling metrics-driven support for conceptual design by both expert and novice designers.

Release Date: January 24, 2026 WASHINGTON -- FEMA announced today that federal disaster assistance is available to the state of South Carolina to supplement response efforts due to emergency conditions resulting from a severe winter storm beginning on January 21, 2026, and continuing. The President’s action authorizes FEMA to coordinate all disaster relief efforts to alleviate the hardship and suffering caused by the emergency on the local population and to provide appropriate assistance to save lives, to protect property, public health and safety and to lessen or avert the threat of a catastrophe in all 46 counties and the Catawba Indian Nation. Specifically, FEMA is authorized to identify, mobilize and provide, at its discretion, equipment and resources necessary to alleviate the impacts of the emergency. Emergency protective measures, limited to direct federal assistance, under the Public Assistance program, will be provided at 75% federal funding. Darryl L. Dragoo has been named the Federal Coordinating Officer for federal response operations in the affected area. Designations may be made at a later date if requested by the state and warranted by the results of further damage assessments. Download Press Release PDF Accessible TXT Tags: Headquarters Region 4 South Carolina 3632 News & Media Newsroom Articles Winter Storm